|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:affects
|
not fully known
|
|
gptkbp:approves
|
gptkb:Europe
gptkb:FDA
gptkb:USA
|
|
gptkbp:atccode
|
L04 AA12
|
|
gptkbp:brand
|
gptkb:Mavenclad
|
|
gptkbp:clinical_trial
|
gptkb:CLARITY_3_study
gptkb:CLARITY_study
Phase 3
Phase III
CLARITY 2 study
CLARITY extension study
ORACLE study
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe liver impairment
lactation
active infection
|
|
gptkbp:developed_by
|
gptkb:Abb_Vie
|
|
gptkbp:dosage_form
|
gptkb:tablet
two treatment courses
once daily for 5 days
once daily for 5 days in the second year
|
|
gptkbp:drug_interactions
|
live vaccines
immunosuppressive drugs
|
|
gptkbp:duration
|
2 years
|
|
gptkbp:effective_date
|
gptkb:2017
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:first_course_dosing
|
10 mg per day for 5 days
|
|
gptkbp:formulation
|
oral tablet
|
|
gptkbp:healthcare
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mavenclad
|
|
gptkbp:ingredients
|
gptkb:cladribine
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
improves quality of life
reduces disability progression
reduces relapse rates
|
|
gptkbp:is_monitored_by
|
infections
liver function
blood cell counts
blood counts
|
|
gptkbp:manufacturer
|
gptkb:Eisai_Co.,_Ltd.
gptkb:Abb_Vie
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:Canada
gptkb:USA
gptkb:Mavenclad
|
|
gptkbp:mechanism_of_action
|
gptkb:immunotherapy
|
|
gptkbp:packaging
|
gptkb:bottle
blister pack
|
|
gptkbp:patient_population
|
available online
adults
relapsing forms of MS
|
|
gptkbp:pharmacokinetics
|
metabolized in liver
bioavailability 100%
half Life 7 hours
|
|
gptkbp:previous_name
|
gptkb:cladribine
|
|
gptkbp:price
|
varies by country
|
|
gptkbp:provides_guidance_on
|
included in MS treatment guidelines
|
|
gptkbp:release_region
|
gptkb:Australia
gptkb:Canada
gptkb:Japan
gptkb:USA
EU countries
|
|
gptkbp:requires
|
available online
prescription only
|
|
gptkbp:research
|
gptkb:CLARITY_study
CLARITY Extension study
ORACLE-MS study
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
recommended during treatment
|
|
gptkbp:second_course_dosing
|
10 mg per day for 5 days after 1 year
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
infections
|
|
gptkbp:storage
|
room temperature
protected from light
protected from moisture
|
|
gptkbp:structure
|
C10 H12 Cl N5 O4 S
|
|
gptkbp:symbolism
|
yes
|
|
gptkbp:treatment
|
gptkb:immunotherapy
disease-modifying therapy
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:used_for
|
gptkb:multiple_sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Merck_Serono
|
|
gptkbp:bfsLayer
|
5
|